MTI Top 100: Leading Medtechs See Steady Organic Growth In A Market On The Cusp Of Change
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
You may also be interested in...
The barriers for health-care industry entrants into China are lowering, but still not as quickly as many medtech companies would like. New structural health-care delivery plans are instilling more confidence in a market and industry that in the past have been regarded with caution.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.